DailyIQ
|
Sector:HealthcareAll sectors
Last updated 15 minutes ago

PODD·Insulet Corporation

$.
+. (+.%)
After Hours
High
$161.82
Open
$159.21
Market Cap
11.17B
52W High
$354.88
Low
$158.30
P. Close
$161.27
P/E
36.88
52W Low
$138.79
Fwd P/E
19.99
DailyIQ Est.
$259.11
Technical Score (1D)
59
BUY
News Sentiment
60
BULLISH
A class action lawsuit alleging securities fraud tied to product safety has been filed against Insulet Corporation, raising immediate concerns about potential regulatory scrutiny and investor confidence. This development could prompt tighter oversight and affect the company’s valuation over the next 1–10 trading days. Investors should monitor court filings and any settlement negotiations for indications of the lawsuit’s trajectory. The lawsuit also highlights possible weaknesses in the company’s product safety processes, which could impact future earnings and operational stability. Any regulatory findings could lead to increased compliance costs and affect the company’s cost of capital. The August 31, 2026 deadline for investors to secure lead counsel underscores the urgency of the situation. Stakeholders should watch for executive responses and any statements from the company’s legal team. The outcome of the lawsuit may influence investor sentiment and could lead to changes in the company’s governance structure. Keep an eye on subsequent court filings and any updates from the SEC regarding potential investigations.
Earnings Summary
Insulet Corporation is a medical‑device company focused on insulin delivery, offering the Omnipod 5 automated system and the Omnipod DASH platform, and supplying pods for Amgen’s Neulasta Onpro kit. In the medical‑devices sector, Insulet has consistently outperformed peers by expanding its product portfolio and securing regulatory approvals across markets. The company’s recent quarterly results show a strong EPS trajectory: Q4 2024 EPS of $1.15 beat the $1.02102 estimate, Q1 2025 EPS of $1.02 beat $0.78642, Q2 2025 EPS of $1.17 beat $0.92264, Q3 2025 EPS of $1.24 beat $1.14745, Q4 2025 EPS of $1.55 beat $1.17827, and Q1 2026 EPS of $1.42 beat $1.1907, marking six consecutive beats. Revenue, however, has slowed after Q4 2025: it fell from $597.5 million in Q4 2024 to $569 million in Q1 2025, then rose to $649.1 million in Q2 2025, $706.3 million in Q3 2025, $783.8 million in Q4 2025, and dipped to $761.7 million in Q1 2026, reflecting a deceleration in growth. Historically, Insulet has maintained a streak of EPS beats while revenue growth has moderated, indicating a shift toward higher margins. Recent analyst coverage highlights Deutsche Bank’s new Buy rating and $190 target, underscoring confidence in the company’s leadership in the tubeless insulin‑pump market; the coverage follows the firm’s latest quarterly results that beat expectations. Additionally, the launch of Omnipod 5 and the Discover data platform in Spain expands the company’s European footprint and could drive future revenue. Going forward, investors should watch for the Q2 2026 earnings release, guidance on revenue and margin expansion, regulatory approvals in new markets, and competitive pressure from GLP‑1 drugs and pharmacy‑channel rivals, as these factors will shape the company’s near‑term performance.

EPS

EstBeatMiss
$0.67$0.92$1.17$1.42$1.66Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$1.45 - -
Q1'26$1.19$1.42+19.3%
Q4'25$1.18$1.55+31.5%
Q3'25$1.15$1.24+8.1%
Q2'25$0.92$1.17+26.8%
Q1'25$0.79$1.02+29.7%

Revenue

EstBeatMiss
$534M$610M$686M$762M$838MQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$803M - -
Q1'26$730M$762M+4.3%
Q4'25$714M$784M+9.7%
Q3'25 - $706M -
Q2'25 - $649M -
Q1'25 - $569M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

PODD Stock Snapshot

PODD is currently trading at $161.28, giving Insulet Corporation a market cap of 11.17B and a P/E ratio of 36.9. Today's range spans $158.30–$161.82, with shares opening at $159.21 and moving up $0.01 (0.0%) from the prior close. DailyIQ's technical score sits at 59/100 (HOLD) with a news sentiment reading of 60/100.

Over the past year PODD has traded between $138.79 and $354.88 - the current price is +16.2% off the 52-week low and -54.6% from the high. 37 analysts cover the stock with a Buy consensus and a mean 12-month target of $238.67 (range $172.00–$360.00), implying upside of +48.0%.

The technical picture for PODD is mixed - score 59/100, HOLD, with the stock at $161.28 (near 52-week lows) and sentiment bullish at 60/100. For a large-cap in Healthcare with 11.17B in capitalization The current P/E ratio stands at 36.9., this is a fairly common pre-earnings or pre-macro-event posture. Annual range: $138.79–$354.88. Neutral signals at this size often resolve sharply once a catalyst provides directional conviction.

The 52-week range of $138.79–$354.88 for PODD provides the structural reference that options traders, systematic funds, and discretionary managers all anchor to — and at $161.28 (near 52-week lows), the stock sits in a zone where the next 5–10% move will likely define which crowd was right. A HOLD signal at 59/100 and bullish news backdrop (60/100) don't break the tie yet, but they narrow the probability distribution toward the upside.